Stockreport

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update

Humacyte, Inc.  (HUMA) 
PDF -Biologics License Application (BLA) for HAV™ Accepted by FDA on February 8, 2024- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for Aug [Read more]